Close Menu

Team GenomeWeb

Premium

Front row, L to R: Marian Moser Jones, editor, BioArray News; Harry Greenwald, COO and publisher; Erika Rullman, BioInform and BioArray circulation sales and marketing; Marina Gulko, circulation assistant

Second row, L to R: Paul Towlen, director of business development; Sofia Minchenko, accountant; Meredith Salisbury, managing editor, Genome Technology; Adrienne Burke, editorial director; Miriam Smith, circulation manager; Karen Richmond, administrator

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.